ArticleO&G open2026
Assessing the Role of Cardiac Disease in Severe Maternal Morbidity: A Population-Based Cohort Study.
Article in O&G open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Congenital heart disease in pregnancy and severe maternal morbidity: a distributed data network study.Pregnancy (Hoboken, N.J.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate whether people with cardiac disease were at increased odds of nontransfusion severe maternal morbidity (SMM) and specific types of SMM during delivery hospitalization through 42 days postpartum compared with those without cardiac disease.
methodsWe conducted a retrospective cohort study using linked birth certificate and hospital discharge data. The study included singleton deliveries at 20-44 weeks of gestation in California from 2007 to 2020. People with cardiac disease before delivery hospitalization were identified with diagnosis codes. The presence of nontransfusion SMM from delivery through 42 days postpartum was chosen as the primary outcome because blood transfusion alone without other SMM occurs often during delivery hospitalization and is nonspecific. Odds of SMM were examined by type in logistic regression models adjusted for confounding factors. Timing of nontransfusion SMM events (during delivery or postpartum) was also examined.
resultsOf 5,848,486 eligible births, 30,359 (0.5%) were to individuals with preexisting cardiac disease. People with cardiac disease had significantly increased odds of nontransfusion SMM (9.1% vs 0.8%, adjusted odds ratio [AOR] 6.88, 95% CI, 6.57-7.19) and SMM with transfusion (11.5% vs 1.7%, AOR 4.69, 95% CI, 4.50-4.88). Odds of cardiac SMM (AOR 53.49, 95% CI, 49.82-57.40) and pulmonary SMM (AOR 11.79, 95% CI, 10.84-12.81) were especially higher in those with cardiac disease, although all types were increased. Nontransfusion SMM events were more likely to occur during delivery hospitalization (compared with postpartum) in people with cardiac disease compared with those without cardiac disease (91.9% vs 75.5%,
conclusionPeople with cardiac disease have significantly higher odds of all types of SMM, particularly cardiac and pulmonary SMM. These results highlight the broader risks of morbidity from cardiac disease and may guide targeted strategies to reduce SMM at the time of delivery and postpartum.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.